Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)
Introduction Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. Reducing dietary salt consumption is a potentially cost-effective way to reduce blood pressure and the burden of CVD. To date, economic evidence has focused on sodium reduction in food industry or p...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-07-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/11/7/e045929.full |
id |
doaj-6f6aa281f25948719763dfea0c4a6691 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lei Si Maoyi Tian Yishu Liu Xinyi Zhang Yangfeng Wu Jie Yu Jixin Sun Yi Zhao Liping Huang Xiangxian Feng Bo Zhou Xuejun Yin Lijing Yan Ruijuan Zhang Zhixin Hao Jingpu Shi Jianxin Zhang Yuhong Zhang Zhifang Li Yan Yu Ka-Chun Li Nicole Li Darwin Labarthe |
spellingShingle |
Lei Si Maoyi Tian Yishu Liu Xinyi Zhang Yangfeng Wu Jie Yu Jixin Sun Yi Zhao Liping Huang Xiangxian Feng Bo Zhou Xuejun Yin Lijing Yan Ruijuan Zhang Zhixin Hao Jingpu Shi Jianxin Zhang Yuhong Zhang Zhifang Li Yan Yu Ka-Chun Li Nicole Li Darwin Labarthe Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS) BMJ Open |
author_facet |
Lei Si Maoyi Tian Yishu Liu Xinyi Zhang Yangfeng Wu Jie Yu Jixin Sun Yi Zhao Liping Huang Xiangxian Feng Bo Zhou Xuejun Yin Lijing Yan Ruijuan Zhang Zhixin Hao Jingpu Shi Jianxin Zhang Yuhong Zhang Zhifang Li Yan Yu Ka-Chun Li Nicole Li Darwin Labarthe |
author_sort |
Lei Si |
title |
Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS) |
title_short |
Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS) |
title_full |
Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS) |
title_fullStr |
Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS) |
title_full_unstemmed |
Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS) |
title_sort |
protocol for the economic evaluation of the china salt substitute and stroke study (ssass) |
publisher |
BMJ Publishing Group |
series |
BMJ Open |
issn |
2044-6055 |
publishDate |
2021-07-01 |
description |
Introduction Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. Reducing dietary salt consumption is a potentially cost-effective way to reduce blood pressure and the burden of CVD. To date, economic evidence has focused on sodium reduction in food industry or processed food with blood pressure as the primary outcome. This study protocol describes the planned within-trial economic evaluation of a low-sodium salt substitute intervention designed to reduce the risk of stroke in China.Methods and analyses The economic evaluation will be conducted alongside the Salt Substitute and Stroke Study: a 5-year large scale, cluster randomised controlled trial. The outcomes of interest are quality of life measured using the EuroQol-5-Dimensions and major adverse cardiovascular events. Costs will be estimated from a healthcare system perspective and will be sought from the routinely collected data available within the New Rural Cooperative Medical Scheme. Cost-effectiveness and cost-utility analyses will be conducted, resulting in the incremental cost-effectiveness ratio expressed as cost per cardiovascular event averted and cost per quality-adjusted life year gained, respectively.Ethics and dissemination The trial received ethics approval from the University of Sydney Ethics Committee (2013/888) and Peking University Institutional Review Board (IRB00001052-13069). Informed consent was obtained from each study participant. Findings of the economic evaluation will be published in a peer-reviewed journal and presented at international conferences.Trial registration number ClinicalTrials.gov Registry (NCT02092090). |
url |
https://bmjopen.bmj.com/content/11/7/e045929.full |
work_keys_str_mv |
AT leisi protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT maoyitian protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT yishuliu protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT xinyizhang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT yangfengwu protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT jieyu protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT jixinsun protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT yizhao protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT lipinghuang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT xiangxianfeng protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT bozhou protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT xuejunyin protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT lijingyan protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT ruijuanzhang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT zhixinhao protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT jingpushi protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT jianxinzhang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT yuhongzhang protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT zhifangli protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT yanyu protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT kachunli protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT nicoleli protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass AT darwinlabarthe protocolfortheeconomicevaluationofthechinasaltsubstituteandstrokestudyssass |
_version_ |
1721216951133405184 |
spelling |
doaj-6f6aa281f25948719763dfea0c4a66912021-08-07T16:33:07ZengBMJ Publishing GroupBMJ Open2044-60552021-07-0111710.1136/bmjopen-2020-045929Protocol for the economic evaluation of the China Salt Substitute and Stroke Study (SSaSS)Lei Si0Maoyi Tian1Yishu Liu2Xinyi Zhang3Yangfeng Wu4Jie Yu5Jixin Sun6Yi Zhao7Liping Huang8Xiangxian Feng9Bo Zhou10Xuejun Yin11Lijing Yan12Ruijuan Zhang13Zhixin Hao14Jingpu Shi15Jianxin Zhang16Yuhong Zhang17Zhifang Li18Yan Yu19Ka-Chun Li20Nicole Li21Darwin Labarthe226 The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia 1 The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia 3 The George Institute for Global Health at Peking University Health Science Center, Beijing, China 1 Cancer Research Center of Lyon, UMR INSERM 1052, Lyon, France 8 Clinical Research Institute and School of Public Health, Peking University, Beijing, Beijing, China Department of Emergency, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital, Shanghai, China8 Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China 1 Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China The George Institute for Global Health, UNSW, Sydney, New South Wales, AustraliaChangzhi Medical College, Changzhi, China5 Respiratory Department, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China 1 The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia Global Health Research Center, Duke Kunshan University, Jiangsu, ChinaSchool of Public Health, Xian Jiaotong University, Xi'an, Shaanxi, ChinaThe George Institute for Global Health at Peking University Health Science Center, Beijing, ChinaDepartment of Evidence-based Medicine, First Hospital of China Medical University, Shenyang, ChinaDepartment of Non-communicable Diseases, Center for Disease Control of Heibei, Shijiazhuang, ChinaSchool of Public Health, Ningxia Medical University, Yinchuan, ChinaSchool of Preventive Medicine, Changzhi Medical College, Changzhi, ChinaSchool of Public Health, Xi’an Jiaotong University Health Science Center, Xi'an, ChinaThe George Institute for Global Health, University of New South Wales, Sydney, New South Wales, AustraliaGeorge Clinical, Sydney, New South Wales, AustraliaFeinberg School of Medicine, Northwestern University, Chicago, Illinois, USAIntroduction Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. Reducing dietary salt consumption is a potentially cost-effective way to reduce blood pressure and the burden of CVD. To date, economic evidence has focused on sodium reduction in food industry or processed food with blood pressure as the primary outcome. This study protocol describes the planned within-trial economic evaluation of a low-sodium salt substitute intervention designed to reduce the risk of stroke in China.Methods and analyses The economic evaluation will be conducted alongside the Salt Substitute and Stroke Study: a 5-year large scale, cluster randomised controlled trial. The outcomes of interest are quality of life measured using the EuroQol-5-Dimensions and major adverse cardiovascular events. Costs will be estimated from a healthcare system perspective and will be sought from the routinely collected data available within the New Rural Cooperative Medical Scheme. Cost-effectiveness and cost-utility analyses will be conducted, resulting in the incremental cost-effectiveness ratio expressed as cost per cardiovascular event averted and cost per quality-adjusted life year gained, respectively.Ethics and dissemination The trial received ethics approval from the University of Sydney Ethics Committee (2013/888) and Peking University Institutional Review Board (IRB00001052-13069). Informed consent was obtained from each study participant. Findings of the economic evaluation will be published in a peer-reviewed journal and presented at international conferences.Trial registration number ClinicalTrials.gov Registry (NCT02092090).https://bmjopen.bmj.com/content/11/7/e045929.full |